HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer.

Dr Neil Segal

Dr Segal is an oncologist at the Memorial Sloan Kettering Cancer Center, the oldest and largest private cancer centre in the US. His research interests focus on the development of new therapies and more specifically, ways to use the immune system to treat cancer. This parallels the approach taken with Imugene’s HER-Vaxx vaccine, which aims to activate the patient’s immune system to produce its own antibodies. Dr Segal has further clinical expertise in colorectal, pancreatic, bile duct and other gastrointestinal cancers. He holds a Doctorate of Medicine and Philosophy from University of the Witwatersrand in South Africa.


© Imugene 2018. All rights reserved. ABN 99 009 179 551